A transcriptomic signature predicting septic outcome in patients undergoing autologous stem cell transplantation

Auto-HSCT is based on the administration of myelosuppressive high-dose chemotherapy, followed by infusion of autologous hematopoietic stem cells to obtain hematologic reconstitution. Hematopoietic stem cells (HSCs) infusion reduces chemotherapy-induced myelosuppression period and procedure-related mortality rate below 3% [1 –3]. With few exceptions (solid tumors, autoimmune diseases), auto-HSCT is essentially indicated for selected hematological malignancies and considered as a standard treatment in young patients with MM and for relapsed or refractory lymphoma.

Source: Experimental Hematology - June 7, 2018 Category: Hematology Authors: Labiad Yasmine, Venton Geoffroy, Farnault Laure, Baier C éline, Colle Julien, Mercier Cedric, Ivanov Vadim, Nicolino Corinne, Loriod Béatrice, Fernandez-Nunez Nicolas, Torres Magali, Mattei Jean-Camille, Rihet Pascal, Nguyen Catherine, Costello Régis Source Type: research